

ONLINE SUPPLEMENTARY DATA

Supplementary Table 1. Clinical characteristics at study entry and at 1, 3, and 5 years post study entry

Supplementary Table 1A, in overall cohort (SLEDAI-2K ≥6)				
	Study entry (where applicable) (N=649)	1 year post study entry (n=649)	3 years post study entry (n=649)	5 years post study entry (n=507)
Disease duration, years, mean (SD)	7.3 (7.6)	8.1 (7.6)	10.1 (7.6)	11.8 (7.4)
SLEDAI-2K score, mean (SD)	11.2 (4.8)	5.8 (5.0)	4.8 (4.7)	4.1 (3.9)
AMS up to years, mean (SD)	n/a	7.0 (3.9)	5.7 (3.3)	5.0 (2.9)
Number of patients with SDI score >0, n (%)	211 (32.5)	231 (35.6)	299 (46.1)	269 (53.1)
SDI score in patients with score >0, mean (SD)	2.0 (1.5)	2.0 (1.5)	2.1 (1.6)	2.2 (1.5)
Steroids at years, n (%)	435 (67.0)	466 (71.8)	433 (66.7)	299 (59.0)
Antimalarials at years, n (%)	333 (51.3)	409 (63.0)	429 (66.1)	324 (63.9)
Immunosuppressants at years, n (%)	209 (32.2)	291 (44.8)	324 (49.9)	213 (42.0)

Supplementary Table 1B, in subcohort of patients with SLEDAI-2K at study entry = 6 OR 7

	Study entry (where applicable) (n=117)	1 year post study entry (n=117)	3 years post study entry (n=117)	5 years post study entry (n=87)
Disease duration, years, mean (SD)	8.8 (8.5)	9.6 (8.5)	11.6 (8.5)	13.0 (8.3)
SLEDAI-2K score, mean (SD)	6.4 (2.6)	3.6 (3.0)	3.1 (3.8)	2.8 (3.2)
AMS up to years, mean (SD)	n/a	4.1 (2.1)	3.4 (2.3)	2.9 (1.9)
Number of patients with SDI score >0, n (%)	44 (37.6)	46 (39.3)	54 (46.2)	41 (47.1)
SDI score in patients with score >0, mean (SD)	1.8 (1.3)	1.9 (1.4)	2.0 (1.4)	2.0 (1.3)
Steroids at years, n (%)	67 (57.3)	68 (58.1)	58 (49.6)	34 (39.1)
Antimalarials at years, n (%)	63 (53.8)	73 (62.4)	76 (65.0)	52 (59.8)
Immunosuppressants at years, n (%)	37 (31.6)	48 (41.0)	49 (41.9)	28 (32.2)

Supplementary Table 1C, in subcohort of patients with SLEDAI-2K at study entry = 8 OR 9

	Study entry (where applicable) (n=122)	1 year post study entry (n=122)	3 years post study entry (n=122)	5 years post study entry (n=97)
Disease duration, years, mean (SD)	7.4 (8.2)	8.1 (8.2)	10.1 (8.2)	11.9 (8.3)
SLEDAI-2K score, mean (SD)	8.2 (0.4)	4.1 (3.2)	3.5 (3.5)	3.0 (2.5)
AMS up to years, mean (SD)	n/a	5.2 (2.1)	4.2 (2.3)	3.7 (2.0)
Number of patients with SDI score >0, n (%)	37 (30.3)	41 (33.6)	49 (40.2)	45 (46.4)
SDI score in patients with score >0, mean (SD)	1.9 (1.0)	2.0 (1.0)	2.0 (1.0)	2.1 (1.1)
Steroids at years, n (%)	60 (49.2)	70 (57.4)	64 (52.5)	41 (42.3)
Antimalarials at years, n (%)	70 (57.4)	88 (72.1)	87 (71.3)	69 (71.1)
Immunosuppressants at years, n (%)	28 (23.0)	40 (32.8)	44 (36.1)	32 (33.0)

Supplementary Table 1D, in subcohort of patients with SLEDAI-2K at study entry ≥ 10

	Study entry (where applicable) (n=410)	1 year post study entry (n=410)	3 years post study entry (n=410)	5 years post study entry (n=323)
Disease duration, years, mean (SD)	6.9 (7.1)	7.7 (7.1)	9.7 (7.1)	11.5 (6.9)
SLEDAI-2K score, mean (SD)	13.4 (4.5)	7.0 (5.4)	5.6 (5.1)	4.8 (4.3)
AMS up to years, mean (SD)	n/a	8.4 (4.0)	6.7 (3.4)	6.0 (2.9)
Number of patients with SDI score >0 , n (%)	130 (31.7)	144 (35.1)	196 (47.8)	183 (56.7)
SDI score in patients with score >0 , mean (SD)	2.0 (1.6)	2.1 (1.6)	2.1 (1.8)	2.2 (1.7)
Steroids at years, n (%)	308 (75.1)	328 (80.0)	311 (75.9)	224 (69.3)
Antimalarials at years, n (%)	200 (48.8)	248 (60.5)	266 (64.9)	203 (62.8)
Immunosuppressants at years, n (%)	144 (35.1)	203 (49.5)	231 (56.3)	153 (47.4)

AMS, adjusted mean SLEDAI; n/a, not applicable; SD, standard deviation; SDI, Systemic Lupus International Collaborating Clinics (SLICC)/American College of Rheumatology (ACR) Damage Index; SLEDAI-2K, Systemic Lupus Erythematosus Disease Activity Index-2000.